Federal Agency for Medicines and Health Products (FAMHP)
Hugues Malonne is the FAMHP's new Chief Executive Officer
Hugues Malonne appointed new FAMHP Chief Executive Officer by the federal government
The FAMHP publishes its annual report 2022: packed with figures and results, special trends and highlighting our most important projects
Although the FAMHP's staff continued to feel the effects of the health crisis, in 2022 they were also able to complete many tasks that had been postponed due to the coronavirus crisis. Various “major” files were started, followed up or closed. For example, new initiatives were launched in collaboration with other national and European institutions to combat the shortage of medicines in Belgium and the European Union. The annual report provides an overview of the FAMHP's main activities and...
The FAMHP publishes its annual report for 2021: all figures and results, trends, activities related to COVID-19 and testimonials from our staff
2021 was the year we gradually returned to our normal way of working at the FAMHP. The high workload caused by the pandemic remained present, but numerous other important projects awaited us, such as the implementation of several European legislations. In addition to the traditional facts and figures, the 2021 annual report includes testimonials that demonstrate the commitment and professionalism of our staff.
The FAMHP publishes its 2020 annual report with testimonials about the first year of the pandemic
In addition to the usual facts and figures, the FAMHP's 2020 annual report includes testimonials from staff members who had to face difficult situations in the field. These stories show that there was tremendous stress and pressure, but also a lot of dedication and professionalism. You might recognize some topics from the daily press coverage we received at the time. Other topics give you a glimpse behind the scenes. In any case, you can now read at first-hand how our staff helped create...
The FAMHP publishes its annual report for 2019
As is customary and with full transparency, the FAMHP publishes the figures and results for 2019 for all its services and activities.
You are receiving this annual report later than you would normally expect from us, as the COVID-19 health crisis has been given priority over the past year. The annual report contains many novelties, rising and falling trends and interesting figures. 2019 was a year of progress, you can read all about it in the FAMHP digital annual report, which is available...
PharmaStatus: a new online application on the availability of medicines
The FAMHP launches PharmaStatus, the new online application that collects information about the availability of medicines in Belgium and makes it public. Current information will help patients, doctors, pharmacists and the pharmaceutical industry to limit the impact of unavailable medicines.
Operation Pangea XII: FAMHP seizes 5,360 packages, containing almost 500,000 counterfeit or illegal products
In 2019, operation Pangea took on a new form. This operation focused on information collection, analysis and communication. For this twelfth edition, that took place from June 2018 to June 2019, the FAMHP provided the necessary data. Pangea is coordinated by INTERPOL and is specifically designed to intercept illegal and counterfeit medicinal products and devices.
The FAMHP releases its annual report for 2018: patients remains at the centre of attention and an ongoing willingness to innovate and remain a quality partner
Improved communication with partner organizations, increased accessibility to innovation for patients with urgent medical needs, an increasingly significant presence on social media … 2018 was marked by exciting developments for the Federal Agency for Medicines and Health Products (FAMHP). You can discover everything in the annual report.
Make medicines safer by reporting side effects in children or during pregnancy or breast feeding. The FAMHP again participates in an international campaign to emphasize the importance of reporting side effects.
The campaign will run from the 19th to the 23rd of November and is part of an awareness week of 32 drug authorities from the EU, South America, the Middle East and Australia.